ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2339

Expression of Type I and Type II Interferons Is Increased in Muscle Biopsies of Juvenile Dermatomyositis Patients and Related to Clinical and Histological Features

Rebecca Nicolai1, Gian Marco Moneta2, Silvia Rosina3, Chiara Fiorillo3, Denise Pires Marafon1, Margherita Verardo4, Luisa Bracci Laudiero5,6, Carlo Minetti3,7, Angelo Ravelli3,8 and Fabrizio De Benedetti1, 1Division of Rheumatology, IRCCS Bambino Gesù Children's Hospital, Rome, Rome, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Roma, Italy, 3University of Genova, Genova, Italy, 4Unit of Neuromuscular and Neurodegenerative Disorders, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Roma, Italy, 5Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Roma, Italy, 6Institute of Translational Pharmacology, CNR, Rome, Italy, Rome, Italy, 7Pediatric Neurology and Muscular Disorders, Giannina Gaslini Institute, Genova, Italy, 8Rheumatology, Giannina Gaslini Institute, Genova, Italy

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: cytokines, interferons and juvenile dermatomyositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Pediatric Rheumatology – Pathogenesis and Genetics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

There is growing evidence for an involvement of interferons (IFNs) in the chronic inflammation that characterizes juvenile dermatomyositis (JDM). The aim of this study was to investigate muscle expression of type I (IFNα/β) and type II (IFNγ) IFN inducible genes in muscle biopsies of JDM patients and their correlations with clinical and histological aspects of the disease.

Methods: In a retrospective cohort of patients diagnosed with JDM (n=35), expression of the six genes part of the so called type I IFN score (IFI27, IFI44L, IFIT1, ISG15, RSAD2, SIGLEC1), as well as of IFNγ and of CXCL9, CXCL10, CXCL11, CIITA, were analyzed by real-time PCR on snap-frozen muscle biopsies and compared with biopsies from Duchenne muscular dystrophy (DMD) patients (n=24) and 4 healthy controls (HC). Expression levels of CXCL9, CIITA (genes specifically induced by IFNγ) and IFNγ itself were used to generate a type II IFN score. We also analyzed mRNA expression of the pro-inflammatory cytokines interleukin- 1β (IL-1β), tumor necrosis factor-α (TNFα) and interleukin-6 (IL-6). Patient charts were reviewed to record clinical features at diagnosis and long term outcomes: physician’s global assessment of disease activity, serum levels of muscle enzymes, erythrocyte sedimentation rate, C-reactive protein level, antinuclear antibodies status, time to inactive disease and time to prednisone (or equivalent) dose 0.2 mg/kg/daily, and relapses. We furthermore evaluated typical histological aspects of JDM (inflammatory infiltrate, necrosis, perifascicular atrophy and fibrosis) on tissue sections of the muscle biopsies.

Results: JDM patients treated (n=12) with systemic glucocorticoids before biopsy were excluded from analysis, because expression levels of the studied genes were markedly reduced compared to untreated patients. The type I IFN score and type II IFN score were significantly higher in the muscle of untreated JDM patients (n=23) compared with controls (p<0.0001, p<0.001 respectively). Expression of TNFα, but not of IL-1β and IL-6, was significantly (p<0.05) higher in untreated JDM muscle biopsies compared with those of controls. Type I IFN score correlated with inflammatory infiltrate and necrosis, while the type II IFN score correlated with inflammatory infiltrate, perifascicular atrophy and fibrosis. Type I IFN score, type II IFN score and TNFα expression significantly correlated with physician’s global assessment at diagnosis (r=0.38, r=0.42, r=0.62, respectively). When analyzing correlations with long term outcomes, we found that patients with elevated type II IFN score reached clinically inactive disease significantly later than patients with low type II IFN score (log-rank chi square value=10.1, p<0.01).

Conclusion: IFN type I and type II scores in muscle biopsies of JDM patients correlate with clinical and histological features suggesting a pathogenic role of IFNs in muscle damage and inflammation in JDM. Noteworthily the type II score correlated with time to clinically inactive disease, suggesting a correlation with disease severity.


Disclosure: R. Nicolai, None; G. M. Moneta, None; S. Rosina, None; C. Fiorillo, None; D. Pires Marafon, None; M. Verardo, None; L. Bracci Laudiero, None; C. Minetti, None; A. Ravelli, None; F. De Benedetti, Novartis, Roche, Pfizer, SOBI, AbbVie, Novimmune, BMS, Sanofi, 2.

To cite this abstract in AMA style:

Nicolai R, Moneta GM, Rosina S, Fiorillo C, Pires Marafon D, Verardo M, Bracci Laudiero L, Minetti C, Ravelli A, De Benedetti F. Expression of Type I and Type II Interferons Is Increased in Muscle Biopsies of Juvenile Dermatomyositis Patients and Related to Clinical and Histological Features [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/expression-of-type-i-and-type-ii-interferons-is-increased-in-muscle-biopsies-of-juvenile-dermatomyositis-patients-and-related-to-clinical-and-histological-features/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expression-of-type-i-and-type-ii-interferons-is-increased-in-muscle-biopsies-of-juvenile-dermatomyositis-patients-and-related-to-clinical-and-histological-features/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology